- <![CDATA[Treatment Intensification Gains Momentum in mCSPC Management]]><![CDATA[During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.]]>onclive · 2mo ago↗ source
- <![CDATA[FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations]]><![CDATA[Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.]]>onclive · 2mo ago↗ source
- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…